UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010478
Receipt number R000012128
Scientific Title Combined Aspirin Study for Mechanical Prosthetic Valve in Kyushu and Ryukyu by Inter-University Hospital Network (ASPIRIN trial)
Date of disclosure of the study information 2013/04/15
Last modified on 2021/10/21 21:19:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Combined Aspirin Study for Mechanical Prosthetic Valve in Kyushu and Ryukyu by Inter-University Hospital Network (ASPIRIN trial)

Acronym

ASPIRIN trial

Scientific Title

Combined Aspirin Study for Mechanical Prosthetic Valve in Kyushu and Ryukyu by Inter-University Hospital Network (ASPIRIN trial)

Scientific Title:Acronym

ASPIRIN trial

Region

Japan


Condition

Condition

Valvular heart disease

Classification by specialty

Cardiology Cardiovascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Comparison of thromboembolic and hemorrhagic events between Japanese patients with mechanical prosthetic valve treated by warfarin alone and those treated by combined warfarin and aspirin.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1) Atherosclerotic events, including stroke, TIA, ischemic heart disease, systemic embolism, peripheral artery disease, and valve thrombosis.
2) Cardiovascular death

Key secondary outcomes

1) All cause death
2) Hemorrhagic events, including intracranial bleeding, gastrointestinal bleeding, bleeding requiring hospitalization and/or blood transfusion, and other significant bleeding
3) gastroduodenal ulcer


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The inclusion criteria were implantation of a mechanical prosthetic valve, age over 20 years, and provided informed consent.

Key exclusion criteria

1) Contraindications to anticoagulant therapy
2) Pregnant patients
3) Feeding patients
4) Patients who were considered not adequate to be included in the study by an attending physician

Target sample size

500


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yutaka Otsuji

Organization

University of Occupational and Environmental Health, Japan, School of Medicine

Division name

The Second Department of Internal Medicine

Zip code


Address

1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

TEL

093-603-1611

Email

otsujiy@med.uoeh-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yuki Tsuda

Organization

University of Occupational and Environmental Health, Japan, School of Medicine

Division name

The Second Department of Internal Medicine

Zip code


Address

1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

TEL

093-691-7250

Homepage URL


Email

yoshimikamio@med.uoeh-u.ac.jp


Sponsor or person

Institute

Yutaka Otsuji

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大分大学医学部附属病院(大分県)、鹿児島大学医学部・歯学部附属病院(鹿児島県)、九州大学医学部附属病院(福岡県)、熊本大学医学部附属病院(熊本県)、久留米大学病院(福岡県)、佐賀大学医学部附属病院(佐賀県)、産業医科大学病院(福岡県)、長崎大学附属病院(長崎県)、福岡大学病院(福岡県)、宮崎大学附属病院(宮崎県)、琉球大学医学部附属病院(沖縄県)


Other administrative information

Date of disclosure of the study information

2013 Year 04 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2013 Year 03 Month 31 Day

Date of IRB

2012 Year 12 Month 19 Day

Anticipated trial start date

2013 Year 06 Month 01 Day

Last follow-up date

2021 Year 06 Month 30 Day

Date of closure to data entry

2021 Year 10 Month 10 Day

Date trial data considered complete

2021 Year 10 Month 31 Day

Date analysis concluded

2021 Year 12 Month 31 Day


Other

Other related information

1) non-randomized prospective observational study
2) Selection of treatment (warfarin alone therapy (W group) or warfarin + low dose aspirin therapy (W + A group)) was left to the attending physicians, who were informed that either treatment allowed.
3) Anticoagulant therapy
The daily dose of warfarin was based on the PT-INR. The target PT-INR level was 1.6 to 3.0. PT-INR will be measured every 2 to 4 weeks after hospital discharge.
4) Anti-platelet therapy
Patients of W + A group will receive 100mg of aspirin per day orally.
5) Follow-up
The patients will be monitored routinely for outcome events during hospitalization and during follow-up at 6 months and 1, 2, 3, 4, 5 years postoperatively.


Management information

Registered date

2013 Year 04 Month 12 Day

Last modified on

2021 Year 10 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012128


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name